Correction to Comment on Metabolic surgery versus conventional therapy in type 2 diabetes (Volume 397, pg 256, 2021)

Research output: Contribution to journalComment/debatepeer-review

Abstract

Miras AD, le Roux CW. Metabolic surgery versus conventional therapy in type 2 diabetes. Lancet 2021; 397: 256–57—In this Comment, the declaration of interest statement for Carel W le Roux has been corrected to read “CWlR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer Ingelheim. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He is the chief medical officer and director of the Medical Device Division of Keyron since January 2011. Both of these are unremunerated positions. CWlR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron's products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron's studies and they are not listed on the stock market. ClR was gifted stock holdings in September 2021 and divested all stock holdings in Keyron in September, 2021. He continues to provide scientific advice to Keyron for no remuneration.” These corrections have been made to the online version as of Feb 3, 2022.

Original languageEnglish
Pages (from-to)520-520
Number of pages1
JournalLancet
Volume399
Issue number10324
Early online date5 Feb 2022
DOIs
Publication statusPublished (in print/issue) - 5 Feb 2022

Bibliographical note

Funding Information:
Miras AD, le Roux CW. Metabolic surgery versus conventional therapy in type 2 diabetes. Lancet 2021; 397: 256–57—In this Comment, the declaration of interest statement for Carel W le Roux has been corrected to read “CWlR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer Ingelheim. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He is the chief medical officer and director of the Medical Device Division of Keyron since January 2011. Both of these are unremunerated positions. CWlR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron's products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron's studies and they are not listed on the stock market. ClR was gifted stock holdings in September 2021 and divested all stock holdings in Keyron in September, 2021. He continues to provide scientific advice to Keyron for no remuneration.” These corrections have been made to the online version as of Feb 3, 2022.

Publisher Copyright:
© 2022 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Correction to Comment on Metabolic surgery versus conventional therapy in type 2 diabetes (Volume 397, pg 256, 2021)'. Together they form a unique fingerprint.

Cite this